Efficacy and Safety of Sarilumab in Hospitalized Patients With Coronavirus Disease 2019: A Randomized Clinical Trial.
COVID-19
hospitalized
interleukin-6 receptor
monoclonal antibodies
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
24 08 2022
24 08 2022
Historique:
received:
12
11
2021
pubmed:
27
2
2022
medline:
30
8
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
Open-label platform trials and a prospective meta-analysis suggest efficacy of anti-interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (COVID-19) receiving corticosteroids. This study evaluated the efficacy and safety of sarilumab, an anti-IL-6R monoclonal antibody, in the treatment of hospitalized patients with COVID-19. In this adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial, adults hospitalized with COVID-19 received intravenous sarilumab 400 mg or placebo. The phase 3 primary analysis population included patients with critical COVID-19 receiving mechanical ventilation (MV). The primary outcome was proportion of patients with ≥1-point improvement in clinical status from baseline to day 22. There were 457 and 1365 patients randomized and treated in phases 2 and 3, respectively. In phase 3, patients with critical COVID-19 receiving MV (n = 298; 28.2% on corticosteroids), the proportion with ≥1-point improvement in clinical status (alive, not receiving MV) at day 22 was 43.2% for sarilumab and 35.5% for placebo (risk difference, +7.5%; 95% confidence interval [CI], -7.4 to 21.3; P =.3261), a relative risk improvement of 21.7%. In post hoc analyses pooling phase 2 and 3 critical patients receiving MV, the hazard ratio for death for sarilumab vs placebo was 0.76 (95% CI, .51 to 1.13) overall and 0.49 (95% CI, .25 to .94) in patients receiving corticosteroids at baseline. This study did not establish the efficacy of sarilumab in hospitalized patients with severe/critical COVID-19. Post hoc analyses were consistent with other studies that found a benefit of sarilumab in patients receiving corticosteroids. NCT04315298.
Sections du résumé
BACKGROUND
Open-label platform trials and a prospective meta-analysis suggest efficacy of anti-interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 (COVID-19) receiving corticosteroids. This study evaluated the efficacy and safety of sarilumab, an anti-IL-6R monoclonal antibody, in the treatment of hospitalized patients with COVID-19.
METHODS
In this adaptive, phase 2/3, randomized, double-blind, placebo-controlled trial, adults hospitalized with COVID-19 received intravenous sarilumab 400 mg or placebo. The phase 3 primary analysis population included patients with critical COVID-19 receiving mechanical ventilation (MV). The primary outcome was proportion of patients with ≥1-point improvement in clinical status from baseline to day 22.
RESULTS
There were 457 and 1365 patients randomized and treated in phases 2 and 3, respectively. In phase 3, patients with critical COVID-19 receiving MV (n = 298; 28.2% on corticosteroids), the proportion with ≥1-point improvement in clinical status (alive, not receiving MV) at day 22 was 43.2% for sarilumab and 35.5% for placebo (risk difference, +7.5%; 95% confidence interval [CI], -7.4 to 21.3; P =.3261), a relative risk improvement of 21.7%. In post hoc analyses pooling phase 2 and 3 critical patients receiving MV, the hazard ratio for death for sarilumab vs placebo was 0.76 (95% CI, .51 to 1.13) overall and 0.49 (95% CI, .25 to .94) in patients receiving corticosteroids at baseline.
CONCLUSIONS
This study did not establish the efficacy of sarilumab in hospitalized patients with severe/critical COVID-19. Post hoc analyses were consistent with other studies that found a benefit of sarilumab in patients receiving corticosteroids.
CLINICAL TRIALS REGISTRATION
NCT04315298.
Identifiants
pubmed: 35219277
pii: 6537638
doi: 10.1093/cid/ciac153
pmc: PMC8903479
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
sarilumab
NU90V55F8I
Banques de données
ClinicalTrials.gov
['NCT04315298']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
e380-e388Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002556
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press for the Infectious Diseases Society of America.
Références
J Immunother Cancer. 2020 Aug;8(2):
pubmed: 32784217
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
Clin Trials. 2017 Jun;14(3):264-276
pubmed: 28397569
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
JAMA. 2021 Aug 10;326(6):499-518
pubmed: 34228774
Rheumatology (Oxford). 2020 Feb 1;59(2):292-302
pubmed: 31312844
N Engl J Med. 2021 Apr 22;384(16):1491-1502
pubmed: 33631065
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
N Engl J Med. 2021 Feb 11;384(6):497-511
pubmed: 33264556
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Eur J Intern Med. 2020 Jun;76:36-42
pubmed: 32448770
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
J Med Virol. 2020 Nov;92(11):2368-2370
pubmed: 32472703
Chest. 2020 Oct;158(4):1397-1408
pubmed: 32553536
Nat Med. 2020 Oct;26(10):1636-1643
pubmed: 32839624
Clin Immunol. 2020 May;214:108393
pubmed: 32222466